// App-Quantinova.ai

OP0026 : A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE

Researchers

Presenter

  • R. Smith

Principal Investigators

  • D. Jayne

  • P. A. Merkel

Medical Centers

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • University of Pennsylvania, Philadelphia, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Oraprine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Roche Holding AG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved